Evidence map›Paper›PMID 40993322›Full record

ArticleDiscover oncology2025

Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamics.

Hadi Akbarzadeh Khorshidi, Marzieh Soltanolkottabi, Maarten J IJzerman

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hadi Akbarzadeh KhorshidiCancer Health Services Research, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. hadi.khorshidi@unimelb.edu.au.
Marzieh SoltanolkottabiMechanical and Industrial Engineering Department, University of New Haven, New Haven, USA.
Maarten J IJzermanCancer Health Services Research, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision oncology using biomarkers and genomic testing facilitates individualised diagnosis and consequently treatment for cancer patients. Standard of Care is conducted through assays of biomarkers for treatment selection. However, Whole Genome Sequencing (WGS) provides excessively more information about actionable mutations and complex interventions. Despite its potentials in cancer management, WGS is restricted by its high cost and limited capacity. Implementing WGS is complex because it influences several elements of the care delivery and deals with the dynamic changes in supply, demand, technology, and cost. In this study, we use a System Dynamics (SD) model to evaluate WGS implementation. We also use the developed SD model to conduct sensitivity analysis to derive insights for decision-making on genomic testing scenarios. Various scenarios have been compared by the number of diagnosed patients and total cost. These scenarios have been created through alterations in WGS referral system, capacity, price, and willingness rate as well as testing time across different hospitals. The results showed that referring more patients for WGS will increase the number of diagnosed patients (by 30%), however it will impose more cost on the system (by 20%) due to higher cost of WGS. Therefore, investment strategies toward reducing cost of WGS as well as reimbursement policies can be beneficial to make WGS more economic and accessible. This study shows how the developed SD model can contribute to providing insights for policy makers in finding the optimal way for implementing WGS.

Indexed as

Health policyPrecision oncologySensitivity analysisSystem dynamicsWhole genome sequencing

Identifiers

PMID40993322
PMCPMC12460206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.